ImmuCell Corporation

ImmuCell Corporation, founded in 1982 and a public company since 1987, is an animal health biologics company that develops, manufactures, and sells products designed to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. The company's solutions aim to prevent calf scours, a common disease in neonatal calves globally that causes 30-40% of pre-weaning mortality in many production systems. The company's main product line, First Defense®, uses hyperimmunized bovine colostrum to deliver pathogen-specific antibodies and other bioactive components. First Defense® is designed to provide Immediate Immunity™ through orally administered antibodies against the primary viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It is given at or soon after birth in various forms, such as single-dose boluses, gel formulations delivered by syringe, and multi-dose powder configurations. In the United States, First Defense® products are regulated as veterinary biologics by the U.S. Department of Agriculture's Center for Veterinary Biologics. In Canada, products are regulated by the Canadian Food Inspection Agency, and similar agencies regulate them in other countries. Some product formats are sold as feed supplements regulated by the U.S. Food and Drug Administration. The company's manufacturing processes involve proprietary vaccine development, dairy herd hyperimmunization management, colostrum sourcing and qualification, antibody concentration and purification, blending, fill-finish operations, and final product testing and release. ImmuCell Corporation also uses third parties to manufacture certain product formats. Products are sold through the company's commercial sales organization in partnership with a network of international, national, and regional animal health distributors. The company's manufacturing capacity increased from approximately 3 million units in 2023 to 4.1 million units in 2024, and 4.6 million units in 2025.